NCT00080405已完成1 期
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
The purpose of this study is to characterize the clinical pharmacokinetic and pharmacodynamic profiles of the 2 doses of VELCADE (bortezomib) for Injection. Patients who volunteer to participate in the pharmacogenetic portion of the study, an additional blood sample will be collected before the Cycle 1 Day 1 dose of bortezomib to assess the genotype of drug metabolizing enzymes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
终止
1 期
A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy SmokersSmoking CessationNCT03303911Achieve Life Sciences26
已完成
1 期
Repeated Dose Phase I Study of FYU-981HealthyNCT02348333Fuji Yakuhin Co., Ltd.18
已完成
1 期
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior YearBreast CancerMultiple MyelomaNCT00424983Novartis Pharmaceuticals18
已完成
1 期
Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy SubjectsHealthyNCT01074593Azidus Brasil20
进行中（未招募）
1 期
A 26-day study of cytisine (Tabex®) with multiple evaluations in people who smoke.Smoking cessationEUCTR2017-003257-42-GBAchieve Life Sciences Inc26